Pharmacokinetics
Pharmacokinetic data were available from all 35 patients for both riluzole and sorafenib. The plasma concentration steady state (Cmin,ss) of sorafenib was achieved on C1D8. In this sorafenib/riluzole combination study substantial interpatient variation in sorafenib Cmin,ss was observed at each dose level (Supplementary Table 2). The plasma Cmin,ss levels showed a dose proportional increase with dose escalation from DL 1 to 2 (200 mg qd to 200 mg BID sorafenib), however, there was no proportional increase in Cmin,ss levels with subsequent dose level escalations (